Maravai Lifesciences Holdings, Inc. MRVI
We take great care to ensure that the data presented and summarized in this overview for MARAVAI LIFESCIENCES HOLDINGS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding MRVI
View all-
12 West Capital Management LP New York, NY13.2MShares$93.9 Million9.86% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.7MShares$76.4 Million0.0% of portfolio
-
Black Rock Inc. New York, NY9.73MShares$69.2 Million0.0% of portfolio
-
Braidwell LP Stamford, CT9.02MShares$64.2 Million2.03% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny5.97MShares$42.4 Million0.02% of portfolio
-
Mackenzie Financial Corp Toronto Ontario, A65.86MShares$41.7 Million0.07% of portfolio
-
Jennison Associates LLC4.55MShares$32.4 Million0.02% of portfolio
-
Massachusetts Financial Services CO Boston, MA4.55MShares$32.4 Million0.01% of portfolio
-
Marshall Wace, LLP London, X04MShares$28.5 Million0.04% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny3.88MShares$27.6 Million0.05% of portfolio
Latest Institutional Activity in MRVI
Top Purchases
Top Sells
About MRVI
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as plasmid DNA and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. Maravai LifeSciences Holdings, Inc. was incorporated in 2020 and is headquartered in San Diego, California.
Insider Transactions at MRVI
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Oct 15
2024
|
William E. Martin Iii Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
50,843
-4.89%
|
$406,744
$8.29 P/Share
|
Jul 15
2024
|
Peter Michael Leddy Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,154
-1.35%
|
$41,232
$8.76 P/Share
|
May 28
2024
|
Gtcr Investment Xi LLC |
SELL
Open market or private sale
|
Indirect |
9,940,974
-33.04%
|
$89,468,766
$9.81 P/Share
|
May 28
2024
|
Gtcr Investment Xi LLC |
BUY
Conversion of derivative security
|
Indirect |
8,409,946
+21.84%
|
-
|
May 28
2024
|
Gtcr Investment Xi LLC |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
8,409,946
-7.06%
|
-
|
May 23
2024
|
Gregory T Lucier Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,645
+21.41%
|
$206,450
$10.78 P/Share
|
May 23
2024
|
Susannah Gray Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,645
+20.36%
|
$206,450
$10.78 P/Share
|
May 23
2024
|
John A De Ford Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,645
+28.21%
|
$206,450
$10.78 P/Share
|
May 23
2024
|
Luke Joseph Marker Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,645
+29.68%
|
$206,450
$10.78 P/Share
|
May 23
2024
|
Jessica Hopfield Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,645
+15.71%
|
$206,450
$10.78 P/Share
|
May 23
2024
|
Benjamin James Daverman Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,645
+29.68%
|
$206,450
$10.78 P/Share
|
May 23
2024
|
Anat Ashkenazi Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,645
+25.36%
|
$206,450
$10.78 P/Share
|
May 23
2024
|
Murali Prahalad Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,645
+23.97%
|
$206,450
$10.78 P/Share
|
May 23
2024
|
Sean Laurence Cunningham Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,645
+29.68%
|
$206,450
$10.78 P/Share
|
May 23
2024
|
Constantine S Mihas Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,645
+29.68%
|
$206,450
$10.78 P/Share
|
Apr 30
2024
|
Peter Michael Leddy Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,576
+1.19%
|
$22,880
$5.7 P/Share
|
Apr 30
2024
|
Christine Dolan Officer |
BUY
Grant, award, or other acquisition
|
Direct |
483
+0.19%
|
$2,415
$5.7 P/Share
|
Apr 30
2024
|
Andrew Burch Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,719
+0.41%
|
$8,595
$5.7 P/Share
|
Apr 30
2024
|
Kevin Herde Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,780
+0.53%
|
$8,900
$5.7 P/Share
|
Apr 30
2024
|
Kurt Oreshack General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
341
+0.15%
|
$1,705
$5.7 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 2.49M shares |
---|---|
Conversion of derivative security | 8.41M shares |
Payment of exercise price or tax liability | 142K shares |
---|---|
Sale (or disposition) back to the issuer | 8.41M shares |
Open market or private sale | 9.94M shares |